New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
“Social Smoking” Linked to Disproportionately High Risk of Death from Lung Disease, Lung Cancer
New research presented at the virtual European Respiratory Society International Congress showed "social smokers" are more than twice as likely to die of lung disease vs non-smokers.
New research presented at the European Respiratory Society (ERS) International Congress being held virtually until September 9, 2020, suggests “social smokers” are more than twice as likely to die of lung disease and over 8-times as likely to die of lung cancer vs non-smokers.
The study, titled “Association of low-intensity smoking with respiratory and lung cancer mortality,” also found that the risk of lung cancer mortality for “social smokers” (those who smoke <10 cigarettes/day) is not substantially lower vs heavy smokers (those who smoke ≥20 cigarettes/day).
The researchers – led by Pallavi Balte, PhD, and Elizabeth Oelsner, MD, MPH, both at Columbia University Medical Center in New York – noted that their study suggests that cutting down, or combining, fewer cigarettes with vaping, is not a substitute for quitting.
“Everyone knows that smoking is bad for you, but it’s easy to assume that if you only smoke a little, the risks won’t be too high,” said Balte to the virtual conference, according to an ERS press release. “Previous research suggests that people are cutting down on smoking, for example in the USA the proportion of smokers smoking less than ten cigarettes per day has increased from 16% to 27%. So, we wanted to study the risks to social smokers compared to people who don’t smoke and compared to heavier smokers.”
The study included 18 730 people selected from a multi-ethnic sample of the general US population; mean age was 61 years old, 56% women, 69% white, 13% current smokers. The median follow-up was 17 years, during which 649 participants died from respiratory causes and 560 died from lung cancer.
Researchers calculated the death rates from respiratory disease and lung cancer and then compared these rates between non-smokers, social smokers, and heavy smokers. Researchers took account of other factors that can influence death rates including age, sex, race, education attainment, and body weight.
The results showed that social smokers were 2.5 times as likely to die of respiratory disease and 8.6 times as likely to die of lung cancer vs non-smokers. Social smokers had around half the rate of death from respiratory diseases as heavy smokers, however, their rate of lung cancer death was two-thirds that of heavy smokers.
“You might think that if you only smoke a few cigarettes a day you are avoiding most of the risk. But our findings [sis] suggesting that social smoking is disproportionately harmful. Smoking is dangerous, regardless of whether you are a heavy smoker or a social smoker, so if you don’t want to die of lung cancer or respiratory disease, the best action is to quit completely,” added Balte.
Cancer Rates in Black Individuals Decline but Still Outpace Other Racial, Ethnic Groups, Says American Cancer Society
The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Cancer Screening is Essential for Prevention and Guidance Begins in Primary Care
A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
Mediar Therapeutics and Lilly Enter Global Licensing Agreement for WISP1 Antibody in Idiopathic Pulmonary Fibrosis
The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.
Cancer Rates in Black Individuals Decline but Still Outpace Other Racial, Ethnic Groups, Says American Cancer Society
The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Cancer Screening is Essential for Prevention and Guidance Begins in Primary Care
A family medicine specialist who works with cancer survivorship highlights findings of a study that illustrate how effective screening is and how treatment has changed.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
Mediar Therapeutics and Lilly Enter Global Licensing Agreement for WISP1 Antibody in Idiopathic Pulmonary Fibrosis
The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.